(Q28201899)

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 April 2017

1 reference

The use of mRNA display to select high-affinity protein-binding peptides

21 April 2017

1 reference

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

21 April 2017

1 reference

Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody

21 April 2017

1 reference

Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease

21 April 2017

1 reference

With the benefit of hindsight

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Recombinant antibodies for cancer diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Methods for generating multivalent and bispecific antibody fragments

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Design and application of diabodies, triabodies and tetrabodies for cancer targeting

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Therapeutic antibodies: magic bullets hit the target

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Tumour targeting of humanised cross-linked divalent-Fab' antibody fragments: a clinical phase I/II study

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Renal metabolism of 3'-iodohippuryl N(epsilon)-maleoyl-L-lysine (HML)-conjugated Fab fragments.

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Introduction: bispecific antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Bispecific human IgG by design

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Clinical applications of phage-derived sFvs and sFv fusion proteins

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Fusion of the tissue factor extracellular domain to a tumour stroma specific single-chain fragment variable antibody results in an antigen-specific coagulation-promoting molecule

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Toxin-labeled monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA.

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Antibody-guided enzyme therapy of cancer producing cyanide results in necrosis of targeted cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Phage versus phagemid libraries for generation of human monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Natural and designer binding sites made by phage display technology

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

High-throughput generation and engineering of recombinant human antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Selection of tumor-specific internalizing human antibodies from phage libraries

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Antibodies to human fetal erythroid cells from a nonimmune phage antibody library

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Towards proteome-wide production of monoclonal antibody by phage display

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Isolation of receptor-ligand pairs by capture of long-lived multivalent interaction complexes

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Ribosome display and affinity maturation: from antibodies to single V-domains and steps towards cancer therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Directed evolution of high-affinity antibody mimics using mRNA display

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Flow cytometric screening of cell-based libraries

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Expression of single-chain Fv-Fc fusions in Pichia pastoris

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Diversification and selection mechanisms for the production of protein repertoires: lessons from the immune system

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Advances in directed protein evolution by recursive genetic recombination: applications to therapeutic proteins

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Improved production and function of llama heavy chain antibody fragments by molecular evolution

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Expression of error-prone polymerases in BL2 cells activated for Ig somatic hypermutation

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Biophysical Properties of Camelid VHHDomains Compared to Those of Human VH3 Domains†

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Isolation of the new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Antibodies inhibit prion propagation and clear cell cultures of prion infectivity

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Respiratory syncytial virus: recent progress towards the discovery of effective prophylactic and therapeutic agents

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

The antiviral activity of antibodies in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Intrabody-mediated phenotypic knockout of major histocompatibility complex class I expression in human and monkey cell lines and in primary human keratinocytes

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Antineoplastic effect of anti-erbB-2 intrabody is not correlated with scFv affinity for its target

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Correlation betweenin VitroStability andin VivoPerformance of Anti-GCN4 Intrabodies as Cytoplasmic Inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Functional expression of chimeric receptor genes in human T cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

In situ cytokine therapy: redistribution of clonally expanded T cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021

Autoantigen microarrays for multiplex characterization of autoantibody responses

1 reference

https://api.crossref.org/works/10.1038%2FNM0103-129

7 January 2021